STRIDES PHARMA SCIENCE LIMITED
CIN: L24230MH1990PLC057062
Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A,
Vashi, Navi Mumbai - 400 703, Maharashtra, India
Tel No: +91 22 2789 2924/ 2789 3199
Corp. Office: 'Strides House', Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, Karnataka, India.
Tel No.: +91 80 6784 0000/ 6784 0290
Website: www.strides.com; Email: investors@strides.com

Dear Shareholders,

Sub: Invitation to attend Thirty-fifth Annual General Meeting Annual General Meeting of the Company to be held on Friday, August 14, 2026.

You are cordially invited to attend Thirty-fifth Annual General Meeting (AGM) of the Company scheduled to be held on **Friday, August 14, 2026** at **12:15 hrs IST** through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM). Notice convening the AGM is enclosed herewith.

To enable ease of participation, please find below key details regarding the meeting:

#	Particulars	Details
1)	Link for live webcast of the AGM and for participation through VC	https://emeetings.kfintech.com/ Shareholders may attend the AGM through VC by accessing the above link or by using the remote e-voting credentials. Please refer the instructions of this Notice for further information.
2)	Link for remote e-voting	https://evoting.kfintech.com/
3)	Cut-off date for e-voting	Friday, August 7, 2026
4)	Time period for e-voting	Starts on Monday**, August 10, 2026 at 09:00 hrs IST** Ends on **Thursday, August 13, 2026 at 17:00 hrs IST**
5)	Last date for publishing results of e-voting	On or before Tuesday, August 18, 2026
6)	Contact details of Registrar and Share Transfer Agent (RTA)	Mr. Sashidhar Mannava, Vice President-Corporate Registry/ Mr. Mohan Kumar A, Senior Manager KFin Technologies Limited (formerly known as KFin Technologies Private Limited) Unit: Strides Pharma Science Limited E-mail:einward.ris@kfintech.com; evoting@kfintech.com Toll Free No.: 1800 309 4001
7)	Helpline number for VC participation and e-voting	

8)	Scrutinizer Details	Mr. Gigi Joseph K J, Practicing Company Secretary (ICSI Membership No. F6483 and CP:5576) of M/s. Joseph and Chacko LLP, Company Secretaries, Bengaluru Email: gigi@jandc.in
9)	Strides contact details	Email: investors@strides.com Tel No.: +91 80 6784 0732/ 0734

Best Regards,

For **Strides Pharma Science Limited**

Sd/-
Manjula Ramamurthy
Company Secretary
ICSI Membership No.: A30515

AGM NOTICE

NOTICE is hereby given that **Thirty-fifth Annual General Meeting (AGM)** of the Shareholders of Strides Pharma Science Limited (Company) will be held on **Friday, August 14, 2026, at 12:15 hrs IST** through Video Conference (VC)/ Other Audio-Visual Means (OAVM) to transact the following businesses:

ORDINARY BUSINESS

Item No.1: To receive, consider and adopt the Audited Financial Statements of the Company (including Consolidated Financial Statements) for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditors thereon.

To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

"RESOLVED that Audited Standalone & Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditors thereon, as circulated to the members, be and are hereby received, considered and adopted."

Item No.2: Declaration of Final Dividend for the Financial Year ended March 31, 2026.

To declare a Final Dividend of Rs. 5 per equity share of face value Rs. 10/- each for the Financial Year ended March 31, 2026.

To consider and if thought fit, to pass the following resolution as an ordinary resolution:

"RESOLVED that pursuant to recommendation of Board of Directors of the Company, approval of shareholders of the Company be and is hereby accorded for the payment of a final dividend of Rs. 5/- per equity share of ₹ 10/- each, for the financial year ended March 31, 2026, to all the Shareholders whose names appear in the Register of Members and the records of the Depositories as on July 31, 2026 ("Record Date")

RESOLVED FURTHER that any Director or Company Secretary of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things and sign and file all such papers, documents, forms and writings as may be necessary and incidental to give effect to the aforesaid resolution".

Item No.3: Re-appointment of Retiring Director.

Pursuant to Section 152 of the Companies Act, 2013, **Mr. Arun Kumar** (DIN: 00084845) retires by rotation and being eligible, offers himself for re-appointment as Director of the Company. Arun is the Founder, Non-Executive Director & Chairperson of the Company.

Relevant details of Mr. Arun Kumar pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India is enclosed as an Annexure 1 to this Notice.

To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

"RESOLVED that pursuant to the provisions of section 152 of the Companies Act, 2013 and rules made thereunder (including any statutory modification and re-enactment thereof and other applicable provisions, if any of the Companies Act, 2013, Mr. Arun Kumar, (DIN: 00084845) who retires by rotation and being eligible has offered himself for re-appointment, be and is hereby re-appointed as a Non-Executive Director of the Company, liable to retire by rotation."

Strides

SPECIAL BUSINESS

Item No.4: Payment of Commission to Non-Executive Directors of the Company in the event of inadequacy of profit.

To consider and if thought fit to pass, with or without modification, the following resolution as a **Special Resolution:**

"**RESOLVED** that pursuant to the provisions of Sections 197, read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (the Act) and Rules framed thereunder, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) (including any statutory modification(s) or re-enactment thereof to the Act and Listing Regulations), based on the recommendations of Board of Directors of the Company, consent of Shareholders of the Company be and is hereby accorded for payment of Commission to Non-Executive Directors (including Independent Directors) (NEDs) of the Company, in the event in any financial year the Company has absence or inadequacy of profit, for an amount not exceeding Rs. 50,00,000 (Rupees Fifty lakhs only) per NED per financial year.

RESOLVED FURTHER that the said Commission be paid to and distributed amongst the NEDs in such amounts or proportions and in such manner as may be directed by the Board of Directors of the Company.

RESOLVED FURTHER that the above payment shall be in addition to the sitting fees payable to NEDs for attending meetings of the Board and/ its Committees or for any other purpose whatsoever, as may be decided by the Board and reimbursement of expenses for participation in the said meetings.

RESOLVED FURTHER that the said approval shall be valid for a period of three years commencing from FY2026-27.

RESOLVED FURTHER that any Director or Company Secretary of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things and sign and file all such papers, documents, forms and writings as may be necessary and incidental to give effect to the aforesaid resolution".

Item No. 5: Appointment of Mr. Aditya Arun Kumar as Non-Executive Director of the Company.

To consider and if thought fit to pass, with or without modification, the following resolution as an **Ordinary Resolution:**

"**RESOLVED** that pursuant to the provisions of Sections 149, 152, 160 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with the rules made thereunder and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and in accordance with the recommendation of the Nomination and Remuneration Committee and the Board of Directors, consent of Shareholders be and is hereby accorded for appointment of Mr. Aditya Arun Kumar (DIN: 06999081) as Non-Executive Director of the Company with effect from June 1, 2026, liable to retire by rotation.

RESOLVED FURTHER that pursuant to the provisions of Sections 149, 197, Schedule V and other applicable provisions, if any, of the Act read with the rules made thereunder, and the applicable provisions of the SEBI Listing Regulations, Aditya shall be entitled to receive the following benefits:

Sitting fee	For attendance at Board and Committee meetings, as per the sitting fees approved and paid to other Non-Executive Directors.
Commission/ Profit sharing	Shall be payable in compliance with Sections 197, read with Schedule V and other applicable provisions, if any, of the Act; And subject to applicable approvals of the Nomination and Remuneration Committee, the Board of Directors and Shareholders of the Company.
Other Benefits	Reimbursement of expenses incurred in connection with business of the Company and in accordance with the Company's applicable policies. Club membership which was made available to Aditya in his capacity of Executive Director shall continue as a transitional/ residual facility for FY2026-27 and shall not be renewed thereafter.

RESOLVED FURTHER that any Director or Company Secretary of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things and sign and file all such papers, documents, forms and writings as may be necessary and incidental to give effect to the aforesaid resolution".

Item No. 6: Appointment of Mr. Venkata Seetharama Raju Pakalapati as Executive Director of the Company.

To consider and if thought fit to pass, with or without modification, the following resolution as a **Special Resolution:**

"RESOLVED that in accordance with the provisions of Sections 196, 197 and 203 read with Schedule V and other applicable provisions of the Companies Act, 2013 ("the Act"), The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 & other applicable Rules framed there under, applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("the Listing Regulations") (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), & Articles of Association of the Company, recommendation of the Nomination and Remuneration Committee ("NRC") and approval of the Board of Directors of the Company, consent of Shareholders of the Company is accorded for appointment of **Mr. Venkata Seetharama Raju Pakalapati (DIN: 07500141) ("Ramaraju/ Ram")** as Executive Director of the Company for a period of three years with effect from June 1, 2026 upto May 31, 2029 (both days inclusive), liable to retire by rotation.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 197 and 203 read with Schedule V and other applicable provisions, if any, of the Act read with Rules made thereunder, and the applicable provisions of the SEBI Listing Regulations, Ram shall be entitled to receive the following remuneration/ benefits:

Fixed Pay	Rs. 3.60 crores per annum
Variable Pay	40 % of Fixed pay i.e., Rs. 1.44 Crores per annum Pay-out shall be linked to Company's performance against the Board-approved Annual Business Plan KPIs as per the Variable Pay Framework

	which forms part of the Strides' Nomination & Remuneration Policy.
Total	Rs. 5.04 crores per annum
Incentive for achievement of Long Term Goals	Long Term Goals of Ram is linked to aspects such as Manufacturing and Supply Chain Leadership, Sustainable Strategy and aligned operations, ESG Integrations across manufacturing, operational excellence, capability & talent development, Digital manufacturing, AI & Automation and Cost Management. Incentive payment shall be considered at the end of the three-year tenure of Ram, depending upon the achievement of the above goals agreed between Ram and the Board. The achievement of long-term goals shall be tracked on an annual basis. Quantum of pay out shall be recommended by NRC and approved by the Board, which shall be further subject to Shareholders' approval.
Other benefits	a) Insurance and other Employee Benefits as per Company Policy; b) Encashment of unavailed leave as per Company's Policy. c) Reimbursement of business-related expenses. d) One Club Membership e) Chauffeur driven car for Company business.
Stock Options	Ram was granted 25,000 Stock Options with an exercise price Rs. 635/- per on May 22, 2024 pursuant to Strides Employee Stock Option Plan 2016. Exercise price for the options were adjusted to Rs. 567/- per option during Jan 2025 to factor the impact of demerger of Identified Business to OneSource Specialty Pharma Limited. Of the options granted, 5,000 options were vested and exercised by Ram during July 2025. Status of vesting and exercise of remaining stock options are as under: • FY 2026: 7,500 options – Vested and due for exercise during FY 27 • FY 2027: 12,500 options – Unvested. Perquisites arising out of exercise of ESOPS shall form part of the remuneration in addition to the remuneration approved above.
Annual Increment	Ram shall be entitled for an annual increment in Fixed Pay, which shall be in line with the average pay hike of Strides' employees for the respective financial year, subject to a cap of 15% of the then Fixed Pay – as recommended by NRC and approved by Board of Directors of the Company. Variable Pay shall be 40% of the revised Fixed Pay.
Minimum remuneration in case of Inadequacy of profits.	In terms of the applicable provisions and Schedule V of the Companies Act, 2013, where in any financial year during the tenure of Ram, the Company has no profit, or its profits are inadequate, remuneration comprising of salary, perquisites and other benefits and emoluments approved herein (including the revision in remuneration as may be approved by the Nomination & Remuneration Committee and Board of Directors from time to time) be continued to be paid as Minimum Remuneration to Ram for a period not exceeding three years.

RESOLVED FURTHER that any Director or Company Secretary of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things and sign and file all such papers, documents, forms and writings as may be necessary and incidental to give effect to the aforesaid resolution".

By Order of the Board
For Strides Pharma Science Limited

Sd/-
Manjula Ramamurthy
Company Secretary
ICSI Membership No.: A30515

Place: Bengaluru
Date: July 20, 2026

Strides

EXPLANATORY STATEMENT
(Pursuant to Section 102 of the Companies Act, 2013)

Pursuant to Section 102 of the Companies Act, 2013 (**Act**), Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and the applicable Secretarial Standards, the following explanatory statement sets out all the material facts relating to the business mentioned under **Item No. 4, 5 and 6** of this Notice:

Item No.4: Payment of Commission to Non-Executive Directors of the Company in the event of inadequacy of profit.

Pursuant to the provisions of Section 197 read with Schedule V of the Companies Act, 2013 ('Act'), payment of commission to NED is permissible as under:

1	In case of adequacy of profits	Where the Company has adequate profits in a financial year and has a Managing Director, Whole-time Director or Manager, the Non-Executive Directors are eligible to receive commission not exceeding one percent of the net profits of the Company.
2	In case of absence/ inadequacy of Profits in any financial year	Where the Company has no profits or inadequate profits in any financial year, remuneration may be paid to Non-Executive Directors in accordance with the limits prescribed under Schedule V of the Act. Further, pursuant to the proviso to Section II of Part II of Schedule V of the Act, remuneration in excess of the prescribed limits may be paid upon approval of the shareholders by way of a Special Resolution. Such commission shall be in addition to the sitting fees payable for attending meetings of the Board and its Committees and reimbursement of expenses incurred in connection with the business of the Company. Further, pursuant to Section 197 of the Act and Regulation 17(6)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, payment of remuneration, fees or compensation to Non-Executive Directors, including Independent Directors, requires approval of the shareholders.

Existing shareholders' approvals obtained by Strides in line with the statutory provisions is listed hereunder:

1 In the case of adequacy of profits

Shareholders of the Company at their Annual General Meeting held on July 30, 2019 had approved payment of Commission to Non-Executive Directors (including Independent Directors) (NEDs) of the Company for an amount not exceeding 1% of Net Profits of the Company.

The said approval shall continue to be valid for payment of Commission to NEDs in the event of adequacy of profits.

2	**In the case of absence/ inadequacy of profits**

Shareholders of the Company at their Annual General Meeting held on August 28, 2023, had approved payment of Commission to NEDs of the Company in case of inadequacy of profits, in accordance with the limits prescribed under Schedule V of the Act.

The approval was valid for a period of three years commencing from FY 2023-24 and ending with FY 2025-26.

Accordingly, fresh approval of the shareholders is being sought for a further period of three years commencing from FY 2026-27.

Historical Commission Paid (last three financial years)

Financial Year	Amount	Remarks
2023-24	Rs. 20 Lakhs per NED	Commission was paid in proportion to the period of office held by respective Directors during the financial year.
2024-25	Rs. 25 Lakhs per NED	
2025-26	Rs. 28 Lakhs per NED	

Current proposal

Pursuant to the recommendations of NRC and Board of Directors of the Company, as approved at their meeting held on May 18, 2026, it is proposed to pay Commission of an amount not exceeding Rs. 50,00,000 (Rupees Fifty lakhs only) per Director per financial year to Non-Executive Directors (including Independent Directors), in the event the Company has no profit or has inadequacy of profit in any financial year. The said approval shall be valid for a period of three years commencing from FY 2026-27.

Payment of such Commission shall be in addition to the sitting fees for attending Board/ Committee meetings and reimbursement of expenses for attending the meetings of the Board, Committee and/ or other meetings.

Commission shall be paid to the Non-Executive Directors in such amount or proportion and in such manner as may be determined by the Board of Directors from time to time, having regard to the performance of the Company and the evaluation of each such Director.

Amount of commission is being recommended keeping in view roles and responsibilities of the Non-Executive Directors including Independent Directors and expectations from NED's in terms of time commitment, knowledge & expertise across several areas such as specific industry knowledge, business strategy, risk management, financial management, corporate governance etc.

In determining the commission payable to each NED, Board may consider, inter alia, factors such as the strategic oversight and guidance provided, level of Board engagement, contribution to Committee deliberations, role in ESG and risk oversight, attendance at Board and Committee meetings, chairmanship or membership of Committees, time commitment, contribution to special assignments, if any, and the outcome of the Board evaluation process.

Shareholders may kindly note that if annual remuneration payable to any single NED exceeds fifty percent of the total annual remuneration payable to all NEDs (in any financial year) separate approval of shareholders by special resolution shall be obtained in terms of Regulation 17(6)(ca) of Listing Regulations.

Non-Executive Directors and Promoter Directors of the Company may be deemed to be concerned/ interested in the said resolution to the extent of commission that may be payable to them.

None of the Executive Directors, Key Managerial Personnel and other Promoters or their relatives are in any way concerned or interested, financially or otherwise, in the resolutions except to the extent of their shareholding, if any in the Company.

Board recommends passing of the proposed resolution stated in Item No. 4 of the Notice for approval by the Shareholders by way of Special Resolution.

Item No. 5: Appointment of Mr. Aditya Arun Kumar as Non-Executive Director of the Company.

Aditya was appointed as Executive Director – Business Development for a term of three years with effect from June 1, 2024.

With a view of professionalizing Strides' management and reducing Promoter Group's direct involvement in operational responsibilities, Aditya has expressed his intention to **transition from executive role to a non-executive role** on the Board of the Company with effect from **June 1, 2026.**

Board of Directors of the Company, pursuant to the recommendation of Nomination & Remuneration Committee in their meeting held on May 18, 2026, unanimously approved appointment of Mr. Aditya Arun Kumar as a Non-Executive Director, liable to retire by rotation.

Consequent to the proposed transition as Non-Executive Director, Aditya ceased to hold office as Executive Director – Business Development with effect from end of business hours of May 31, 2026, and is not in employment of the Company.

Relevant details of Aditya pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India is provided hereunder:

About Aditya

Aditya, aged about 37 years, is a Promoter Director of the Company. He holds a bachelor's degree in biomedical sciences from Newcastle University and a Master of Research in Biophysics from Kings College, London.

Aditya has been associated with the Strides Group since 2013. Over the last thirteen years, he has held multiple roles across Strides and the Promoter Family Office, contributing meaningfully across business development and strategic initiatives. As Executive Director, Aditya led business development across Africa and New Markets and played an instrumental role in expanding partnered and B2B businesses.

Aditya has over 13 years of experience in the pharmaceutical industry, predominantly in Business Development and strategy roles. Prior to heading the B2B business at Strides, he was responsible for the integration of two acquired consumer healthcare divisions.

Between 2017 and 2022, Aditya led a promoter funded pharmaceutical start up focused on oral lyophilized dosage forms, which represents one of the limited technology platforms globally with integrated development and manufacturing capabilities.

Since June 2022, he has been leading Strides' Global Partnered Business, where he has played a key role in onboarding new customers across geographies and scaling the business in terms of size, scope, and sustainability. In the new role as Non-Executive Director, shall continue to provide strategic guidance and direction to Business Development initiatives of the Company.

Disclosures/ Declarations received from Aditya

Company has received all statutory disclosures/ declarations from Aditya including:

a) Consent in writing for appointment as Non-Executive Director in Form DIR-2, pursuant to Rule 8 of the Companies (Appointment and Qualifications of Directors) Rules, 2014 ("the Appointment Rules").

b) Intimation in Form DIR 8 in terms of the Appointment Rules to the effect that he is not disqualified under sub-section (2) of Section 164 of the Act.

c) Declaration pursuant to BSE Circular No. LIST/ COMP/ 14/ 2018-19 dated June 20, 2018, and NSE Circular No. NSE/ CML/ 2018/ 24 dated June 20, 2018 that he has not been debarred from holding office of a Director by virtue of any order passed by the SEBI or any other such authority.

Other Directorships held by Aditya is as under:

#	Name of entity	Position held
	Strides Group entities	
1	Strides Consumer Private Limited	Director
2	UCL Brands Limited, Kenya	Director
3	Universal Corporation Limited, Kenya	Director
4	Amexel Pte Limited, Singapore	Director
	Other Companies	
5	Velbiom Probiotics Private Limited	Director
6	InstaPill Private Limited, United Kingdom (formerly known as Tenshi Kaizen Private Limited, U.K.,)	Director
7	Steriscience Private Limited, United Kingdom	Director
8	Karuna Group LLP	Designated Partner
9	Oleander Pharmaceuticals Pte. Limited	Director

Note: Aditya has not resigned from the directorship of any listed entity during the last three years, except for his resignation from his executive position in Strides. He does not hold Membership/ Chairmanship of any committee of other companies.

During FY 2025-26 till the date of this Notice, attendance of Aditya in Board/ Committee meetings is as under:

Board/ Committee	No. of Meetings held.	No. of meetings attended
Board Meetings	9	9
Risk Management & Sustainability Committee	3	1
CSR Committee	1	1

Note: Aditya is also part of the CSR Committee effective January 31, 2026.

Shareholding and other pecuniary relationships with the Company

a) Aditya is part of Strides' Promoter Group and holds 58,422 equity shares of Strides as at the date of this Notice which is ~ 0.06% of Strides' paid-up capital.

b) Details of last drawn remuneration:

Financial Year	Fixed Pay	Variable Pay	Total Remuneration
2023-24	Rs. 75 Lakhs	Rs. 25 Lakhs	Rs. 1 Cr
2024-25	Rs. 1.37 Cr	Rs. 50.65 Lakhs	Rs. 1.87 Cr
2025-26	Rs. 1.61 Cr	Rs. 80.50 Lakhs	Rs. 2.42 Cr

Notes

- Variable Pay for a particular financial year is paid in the immediately succeeding financial year. For FY 2025-26, variable pay is yet to be paid and shall be paid during FY 27 post evaluation of performance and approval of NRC and Board.
- A club membership facility was originally made available to Aditya during his tenure as Executive Director, this shall be treated as a transitional / residual facility only for FY2026-27 and shall not be renewed thereafter.

c) **Proposed remuneration as Non-Executive Director:** As set out in the resolution.

Recommendation of NRC & Board

NRC at their meeting held on May 18, 2026, considered the proposal for appointment of Aditya as Non– Executive Director of the Company effective June 1, 2026. Declarations provided by Aditya including his consent for the proposed appointment was taken on record.

Aditya's appointment in an executive capacity was undertaken with the objective of providing focused leadership and ensuring stability in driving key strategic growth initiatives of the Company.

NRC noted that during his tenure over the past two years, he has made significant contributions towards scaling the business operations and establishing robust governance frameworks to support sustainable growth. With substantial achievement of the objectives, Aditya has expressed his intention to step down from his executive responsibilities and transition to a Non-Executive role on the Board.

Aditya's transition into Non-Executive position is aligned with the promoters stated objective of further professionalizing the management of the Company and maintaining high standards of corporate governance by adhering to the principle of avoiding potential conflicts of interest and not holding executive positions across listed entities in which they are promoters.

Aditya's profile was mapped with the Board Skill matrix, and it was confirmed that Aditya possesses the requisite qualifications, experience, expertise, and integrity and that his continued association with the Board is aligned with the Company's Board Skill Matrix and Nomination and Remuneration Policy.

NRC ascertained that with over 13 years of experience in various capacities in pharmaceutical industry, Aditya has the right mix of Industry experience and thorough knowledge of Company's internal and external business environment.

Considering the above assessment and rationale, NRC accorded it's assent for Aditya's appointment as Non–Executive Director and accordingly recommended Board for appointment of Aditya as Non-Executive Director of the Company.

Board of Directors at their meeting held on May 18, 2026, concurred with the evaluation and recommendations of NRC and accorded its approval for appointment of Aditya as Non-Executive Director of the Company effective June 1, 2026 (including proposed remuneration).

Recommendation to Shareholders

Considering the above, Board of Directors of the Company recommends appointment of Mr. Aditya Arun Kumar as Non-Executive Director of the Company effective June 1, 2026.

In terms of Section 160 of the Companies Act, 2013, the Company has received notice in writing from a shareholder proposing the candidature of Aditya to be appointed as a Non-Executive Director of the Company.

Aditya is son Mr. Arun Kumar, Non-Executive Director & Chairperson of the Company. He is not related to any other Director/ Key Managerial Personnel of the Company.

Except Mr. Arun Kumar and Mr. Aditya Arun Kumar, who are part of the Promoter Group, and their relatives, none of the other Directors, Key Managerial Personnel, and their relatives are in any way concerned or interested, financially or otherwise, in the resolution except to the extent of their shareholding as Members, if any.

Board recommends passing of the resolution as set out in Item No. 5 of the Notice as Ordinary Resolution and requests Shareholders' approval for the same.

Item No. 6: Appointment of Mr. Venkata Seetharama Raju Pakalapati (DIN: 07500141) as Executive Director of the Company.

Mr. Venkata Seetharama Raju Pakalapati ("Ramaraju/ Ram") is proposed to be appointed as the Executive Director effective June 1, 2026.

Relevant details of Ram pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India is provided hereunder:

About Ram

Ram (Aged about 53 years) has been associated with the Strides Group since 2007. With effect from March 1, 2024, he was appointed as the Chief Operating Officer (COO) of Strides.

Ram holds a master's degree in Pharmaceutical Chemistry and has vast experience in the pharmaceutical and healthcare sectors.

A dynamic and results-oriented executive, Ram has a proven history of spearheading operational strategies that drive business expansion and efficiency. With over two decades of experience in the pharmaceutical and healthcare industry, he excels in developing and implementing innovative solutions that streamline operations, enhance productivity, and yield outstanding outcomes. In his role at Strides, Ram assumes responsibility for overseeing the entirety of Global Operations.

During his association with the Group, Ram has held multiple leadership roles across Strides Pharma and Stelis Biopharma (OneSource), with core responsibilities spanning across quality, manufacturing, and operations. He brings over thirty years of experience in the pharmaceutical industry, of which more than nineteen years have been with the Strides Group, reflecting strong institutional knowledge and long-term commitment.

Prior to joining Strides, Ram was associated with reputed pharmaceutical organizations including Dr. Reddy's Laboratories, USV, and Unichem Laboratories. He holds a post graduate degree in Pharmaceutical Chemistry from BITS Pilani.

With over a decade-long tenure at Strides, he has held various leadership roles within the organization. His leadership approach is characterized by strategic foresight, collaborative synergy, and an unwavering commitment to excellence.

Key areas for roles and responsibilities of Ram as Executive Director, including the short-term and long-term goals agreed with the NRC & Board is as under:

Short term goals	Long term goals
• Cost Management and financial discipline. • Compliance & Quality Assurance. • Supply Chain Resilience & Service Levels. • Strategic Project & Facility Execution. • Capital Expenditure & Growth Enablement and • Digital Stability & Analytics Enablement.	• End to End Manufacturing & Supply Chain Leadership • Sustainable & Strategy Aligned Operations • ESG Integration Across Manufacturing • Operational Excellence & Capability Development • Talent Development & Leadership Pipeline • Digital Manufacturing, IT, AI & Automation • Cost Management & Value Creation

Confirmations received from Ram:

Company has received all statutory disclosures/ declarations from Ram including:

a) Consent in writing for appointment as Executive Director in Form DIR-2, pursuant to Rule 8 of the Companies (Appointment and Qualifications of Directors) Rules, 2014 ("the Appointment Rules").

b) Intimation in Form DIR 8 in terms of the Appointment Rules to the effect that he is not disqualified under sub-section (2) of Section 164 of the Act.

c) Declaration pursuant to BSE Circular No. LIST/ COMP/ 14/ 2018-19 dated June 20, 2018, and NSE Circular No. NSE/ CML/ 2018/ 24 dated June 20, 2018 that he has not been debarred from holding office of a Director by virtue of any order passed by the SEBI or any other such authority.

Other Directorships & Whole-time positions held by Ram

Ram holds the position of director (promoter) of Sunspire Life Sciences Private Limited since February 13, 2026. Ram has confirmed that Sunspire Life Sciences is an investment holding company and it's business does not conflict with Strides business.

Except for the said Directorship, Ram does not hold any Directorships/ whole-time positions in any Company/ Body Corporate. Also, he does not hold Membership/ Chairmanship of Committees in other companies.

Ram has not resigned from any listed entity in the past three years.

Till the date of this Notice, Ram has attended two meetings of Board of Directors of the Company.

Shareholding in the Company and other pecuniary relationships

a) As on date of this notice, Ram holds 44,000 equity shares of the Company, representing approximately 0.048% of the paid-up share capital. He also holds 20,000 stock options exercisable during FY 27 and FY 28, which, upon exercise, would result in a holding of approximately 0.069% of the paid-up share capital.

b) Details of last remuneration drawn:

Financial Year	Fixed Pay	Variable Pay*	Total remuneration
2024-25	Rs. 2.68 Crs	Rs. 0. 88 Crs	Rs. 3.56 Crs
2025-26	Rs. 2.90 Crs	Rs. 0.80 Crs	Rs. 3.70 Crs

Note: Variable Pay for a particular financial year is paid in immediately succeeding financial year. For FY 2025-26, variable pay is being paid during FY 27.

Other benefits:

a) One club Membership;
b) Chauffeur driven car for Company business
c) ESOP perquisite of Rs. 16,68,250/- during FY 2026.

c) **Proposed remuneration:** As set out in the resolution.

Quantum of variable pay shall be linked to Company's performance against the Board-approved Annual Business Plan KPIs, as per the following matrix:

Company Performance Score	Pay out as % of allocated Variable Pay
<70%	NIL
70–79%	60% of the target variable pay
80–89%	70% of the target variable pay
90-100%	Linear increase up to 100%
>100%	*Incremental increase of 1% payout for every 1% increase in Company performance (e.g., at 101% achievement, payout will be 102%)* *For Executive Directors, any payout exceeding 100% of the target variable pay shall be subject to prior approval of the shareholders, as per applicable laws and regulations.*

Recommendation of NRC & Board

Nomination and Remuneration Committee ("NRC"), at its meeting held on May 18, 2026, considered the proposal for appointment of Mr. Venkata Seetharama Raju Pakalapati ("Ram") as Executive Director of the Company, including the proposed terms of remuneration. NRC took on record the statutory disclosures and declarations submitted by Ram, including his consent to act as Director.

NRC noted Ram's extensive experience in the pharmaceutical industry, deep institutional knowledge of the Strides Group, and proven leadership track record across manufacturing, quality, supply chain and global operations. His experience across diverse operating environments and complex pharmaceutical businesses has enabled him to develop a strong end-to-end understanding of the Company's operational ecosystem, along with the ability to translate strategy into execution, drive operational efficiencies, and strengthen systems and processes across the value chain.

Ram's profile was evaluated against the Board Skill Matrix, and the NRC confirmed that his experience, expertise and competencies are well aligned with the skills and capabilities identified as critical for the Board, particularly in the areas of operations, strategy execution, governance, digital transformation and leadership continuity.

NRC further observed that Ram's proposed elevation is aligned with the Company's strategic priorities and succession planning framework, and is consistent with the Company's philosophy of nurturing internal talent, strengthening a professional management structure, and ensuring continuity of leadership.

Considering the above assessment and rationale, the NRC accorded its approval for Ram's appointment as Executive Director and recommended the same to the Board.

Board of Directors, at their meeting held on May 18, 2026, concurred with the evaluation and recommendation of the NRC and approved the appointment of Ram as Executive Director of the Company with effect from June 1, 2026, including the proposed remuneration, subject to approval of the Shareholders.

Strides

Recommendation to Shareholders

Board of Directors of the Company recommends appointment of Ram as an Executive Director effective, June 1, 2026.

A copy of the Memorandum of Terms of Appointment with Ram is available for e-inspection by the shareholders of the Company.

In terms of Section 160 of the Companies Act, 2013, the Company has received notice in writing from a Shareholder proposing the candidature of Ram as an Executive Director of the Company.

Ram is not related to any Director/ Key Managerial Personnel of the Company.

None of the other Directors, Key Managerial Personnel, and their relatives are in any way concerned or interested, financially or otherwise, in the resolutions except to the extent of their shareholding as Members, if any.

Board recommends passing of the resolution as set out in Item No. 6 of the Notice as Special Resolution and requests Shareholders' approval for the same.

ANNEXURE 1

DISCLOSURE FOR ITEM NO. 3 OF THE NOTICE UNDER REGULATION 36 OF THE SEBI LISTING REGULATIONS AND SECRETARIAL STANDARD ON GENERAL MEETINGS

 # Particulars

1) Brief resume, Qualification, Experience and Nature of expertise in specific function

Arun Kumar (Aged about 66 years) is the Company's Founder and Promoter Director. Arun is a first-generation entrepreneur with an illustrious track record of pursuing "difficult to operate" domains with high scarcity value. Effective April 5, 2025, Arun has transitioned as Non-Executive Chairperson on the Board of Strides.

Arun founded the Company in 1990 and has since led the Company in establishing a global reputation with a differentiated business model and delivering value to its stakeholders, including distribution of the most extensive dividend by a pharmaceutical company in India.

Arun was awarded the E&Y Entrepreneur of the Year for the Healthcare Industry in 2000. In 2014, he also received the "India's Best CEO Award (Mid-Sized Companies Category)" and "Best CEO in the Pharma and Healthcare Industry" from Business Today.

2) Terms and conditions of Appointment or Reappointment and details of remuneration sought to be paid.

Mr. Arun Kumar was appointed as Non-Executive Director & Chairperson of the Company effective, April 5, 2025, liable to retire by rotation.

Pursuant to Section 152 of the Companies Act, 2013, Mr. Arun Kumar (DIN: 00084845) who retires by rotation and being eligible, offers himself for re-appointment as Director of the Company.

As a Non-Executive Director, Arun receives sitting fees for attending Board & Committee meetings and Commission in line with the payouts to other Non-Executive Directors. Arun is also eligible for Chairman's Office and related expenses as permissible under Listing regulations.

3) Details of last drawn remuneration

As Executive Chairperson (up to April 4, 2025):

Financial Year	Fixed Pay	Variable Pay*	Total remuneration
2023-24	Rs. 6 Crs	Rs. 6 Crs	Rs. 12 Crs
2024-25	Rs. 6.60 Crs	Rs. 2.40 Crs	Rs. 9 Crs
2025-26	Rs. 0.49 Crs	NIL	Rs. 0.49 Crs

As Non-Executive Chairperson (From April 5, 2025 to March 31, 2026):

As a Non-Executive Director, Arun has been paid the following remuneration

- Rs. 10 Lakhs for attending meetings of Board of Directors and Board Committees.
- Rs. 28 Lakhs as Commission for FY 2025-26. Payout of this commission was completed

during May 2026.

4) Shareholding in Strides as at date of this Notice including shareholding as a beneficial owner.

Arun is the Founder and Promoter of the Company and holds along with his relatives ~14.73% of the of the paid-up capital of the Company (including the shares held Directly/ Indirectly).

5) Relationship with other Directors, Managers and Key Managerial Personnel of the Company

Except for Aditya Arun Kumar (Son of Mr. Arun Kumar) none of the other Directors/ Key Managerial Personnel are related to Arun.

6) Membership/ Chairmanship of the Committees of Strides

Arun is a member of Stakeholders Relationship Committee and Nomination & Remuneration Committee of Strides.

7) Number of Board and Committee Meetings attended during FY26 of Strides

During the financial year, Arun was entitled to attend 17 meetings (comprising of Board and Committee meetings). He has attended all the meetings and has an attendance record of 100%.

8) Directorship held in other Companies including listed entities as at date of this Notice

#	Entity Name	Designation
1	Onesource Specialty Pharma Limited	Director
2	Solara Active Pharma Sciences Limited	Director

9) Other Membership/ Chairmanship of Committees of the Board as at date of this Notice

Arun holds the following committee memberships in other entities:

Company Name	Committee Name	Chairman/ Member
Onesource Specialty Pharma Limited	Management Committee	Chairperson
	Environmental, Social and Governance Committee	Member
	Strategic Advisory Committee	Member
Solara Active Pharma Sciences Limited	Management Committee	Member

10) Names of the listed entities from which the Director has resigned in the past three years

Arun has not resigned from the directorship of any listed entity during the last three years.

Strides

Statement of Disclosures as required under schedule V of the Act for payment of remuneration to Executive Director and Commission to Non-Executive Directors when the company has absence or inadequacy of profits in any financial year (item Nos. 4 and 6 of this Notice respectively).

#	Particulars	Details
1	**General Information:**	
a)	Nature of Industry	Pharmaceutical Industry
b)	Date or expected date of commencement of commercial production	Not applicable, as the Company is an existing Company
c)	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus.	
2	**Financial performance based on given indicators**	

(Rs. In millions)

Particulars	Standalone			Consolidated		
	FY 26	FY 25	FY 24 (Restated)	FY 26	FY 25	FY 24 (Restated)
Total Income	23,031.98	21,856.11	19,248.28	50,093.96	46,240.57	39,298.27
Total Expenses (before exceptional items and tax)	21,000.97	21,075.01	19,423.96	43,143.36	42,036.34	38,016.07
Profit After tax	1,836.35	591.56	(242.75)	6,686.86	4,869.21	(1,147.92)

3	Foreign investments or collaborations, if any	As at June 30, 2026, Foreign Holding in the Company was at 30.53%. There are no Foreign Collaborations as at the date of this Notice.
4	**Information about Directors whose remuneration is under approval**	
a)	**Background details, Recognition/ Awards, Job Profile and Suitability to the role**	
	For Non- Executive Directors (Including Independent Directors): Brief profile of Non-Executive Directors, details of their Committee membership at Strides and details of their other Directorships are available in the website of the Company and can be accessed at the weblink given below: https://www.strides.com/about-us/board-of-directors For Executive Director (Mr. Ramaraju PVS) – as detailed out in explanatory statement of	

	Resolution no. 6.
b)	**Past Remuneration and Proposed Remuneration.**
	Past Remuneration for Non-Executive Directors:

(in Rs. Actuals)

	FY 26		FY 25		FY 24	
Name of Director	**Sitting fee**	**Commission**	**Sitting fee**	**Commission**	**Sitting Fee**	**Commission**
Homi Rustam Khusrokhan	16,00,000	28,00,000	20,00,000	25,00,000	20,00,000	20,00,000
Dr Kausalya Santhanam	18,00,000	28,00,000	22,50,000	25,00,000	20,00,000	20,00,000
Ameet Hariani	17,00,000	28,00,000	19,00,000	25,00,000	4,00,000	4,00,000
Subir Chakraborty	17,00,000	28,00,000	12,50,000	2,083,333	-	-
Mukta Arora	15,00,000	28,00,000	1,00,000	516,667	-	-
Arun Kumar	10,00,000	28,00,000	-	-	-	-
Total	**93,00,000**	**1,68,00,000**	**75,00,000**	**1,01,00,000**	**44,00,000**	**44,00,000**

Note: The above information is limited to Directors for whom commission payouts are proposed to be made during the forthcoming financial years. Mr. Aditya Arun Kumar transitioned to the Non-Executive category with effect from June 1, 2026; accordingly, details relating to sitting fees and commission are not applicable to him for the periods covered above.

Past remuneration to Executive Director whose appointment is proposed under item 6 of this Notice.

Please refer to the Explanatory Statement pertaining to this item.

Proposed Remuneration to Ram: As mentioned in the respective resolution.

c) Comparative remuneration profile with respect to industry, size of the company, profile of the position and person.

For Executive Director:

Existing remuneration drawn by Ram as Chief Operating Officer of the Company has been detailed out in explanatory statement pertaining to Item No. 6.

Proposed remuneration recommended by NRC and approved by the Board is in line with the guidelines of the Company's Nomination and Remuneration Policy and aligns with the short-term, medium term and long-term goals of the Company.

Considering Ram's skill set and expertise & the requirement of effective leadership to drive a challenging operation at Strides, remuneration proposed for Ram is comparable and is in the range for similar positions in similar sized companies of the Indian Pharma Industry.

For Non-Executive Directors:

Amount of commission is being recommended keeping in view roles and responsibilities of the Non-Executive Directors including Independent Directors and expectations from NED's in terms of time commitment, knowledge & expertise across several areas such as specific industry knowledge, business strategy, risk management, financial management, corporate governance etc.

d) Reasons of loss or inadequate profits and steps taken or proposed to be taken for improvement and expected increase in productivity and profits in measurable terms

Shareholders' approval by way of a Special Resolution is being sought, having regard to the quantum of remuneration proposed and to ensure continued compliance with the applicable provisions of the Act and Schedule V thereto, including in the event that the Company has no profits or inadequate profits in any financial year during the approved tenure.

Company continues to pursue initiatives aimed at sustaining and improving its operational and financial performance. These include strengthening manufacturing and supply chain efficiencies, enhancing cost discipline, improving product mix, expanding business development opportunities, optimizing working capital, driving digital and automation initiatives, and maintaining focus on quality, regulatory compliance and customer service levels. These measures are expected to support improved operating leverage, productivity and profitability over the medium term.

Company has consistently delivered profits over the years. Accordingly, the proposed resolution is being placed before the Shareholders as an enabling approval, to provide flexibility and ensure continued compliance with the applicable provisions of Schedule V of the Act, should there be any absence or inadequacy of profits during the approved tenure.

*****

NOTES

1) **Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (Act) with respect to the special businesses' forms part of the Notice.**

2) Ministry of Corporate Affairs (**MCA**), Government of India, vide its General Circular No. 14/ 2020 dated April 8, 2020, General Circular No. 17/ 2020 dated April 13, 2020, General Circular No. 20/ 2020 dated May 05, 2020, General Circular No. 10/ 2022 dated December 28, 2022, General Circular No. 09/ 2023 dated September 25, 2023, General Circular No. 09/ 2024 dated September 19, 2024 and General Circular No. 03/ 2025 dated September 22, 2025, and any subsequent circulars issued in this regard (collectively, "**General Circulars**"), and Securities and Exchange Board of India (**SEBI**), vide its Circular No. SEBI/ HO/ CFD/ CFD-PoD-2/ P/ CIR/ 2023/ 167 dated October 07, 2023, Circular No. SEBI/ HO/ CFD/ CFD-PoD-2/ P/ CIR/ 2024/ 133 dated October 03, 2024, read with any subsequent circulars/ relaxations issued by SEBI in this regard (**SEBI Circulars**), have permitted companies to conduct General Meetings through Video Conference (**VC**) or Other Audio-Visual Means (**OAVM**), subject to compliance with the conditions prescribed therein.

3) In compliance with the provisions of the Act, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**Listing Regulations**), General Circulars and SEBI Circulars, AGM of the Company is being held through VC/ OAVM.

   Shareholders can attend and participate in the AGM through VC/ OAVM only.

   In compliance with the applicable provisions of the Companies Act, 2013, the Listing Regulations and applicable circulars, the Notice of the 35th AGM and the Annual Report for FY 2025-26 are being sent electronically to those shareholders whose email addresses are registered with the Company/ Depositories/ RTA.

   Further, in terms of Regulation 36(1)(b) of the SEBI Listing Regulations, the Company shall send a physical communication containing the web-link, including the exact path, to access the complete Annual Report and AGM Notice, to those shareholders whose email addresses are not registered with the Company / Depositories / RTA. Shareholders may request a physical copy of the Annual Report by writing to the Company / RTA.

   Shareholders may note that the AGM Notice and Annual Report for FY26 shall also be available on the Company's website www.strides.com; website of the Stock Exchanges i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), and on the website of KFin Technologies Limited (Formerly known as KFin Technologies Private Limited) (**KFintech/ RTA**) at https://evoting.kfintech.com.

   Shareholders who require printed copy of the Annual Report may write to the RTA/ Company at einward.ris@kfintech.com or investors@strides.com.

   Deemed venue for the AGM shall be Registered Office of the Company.

   Company has appointed KFintech to provide VC/ OAVM facility for 35th AGM of the Company.

   Further, in compliance with the provisions of Section 108 of the Act, read with relevant Rules, Secretarial Standard on General Meetings (SS-2), Regulation 44 of Listing Regulations and General Circulars, the facility for remote e-voting and e-voting in respect of the businesses to be transacted at the AGM is being provided by the Company through KFintech.

General instructions for accessing and participating in the AGM through VC/ OAVM Facility and voting through electronic means including remote e-voting is enclosed as **Annexure 2.**

Shareholders who have cast their vote by remote e-voting prior to the meeting may attend the meeting but will not be entitled to cast their vote again at the meeting.

4) **AGM Live Webcast and two-way conference Facility**

Pursuant to Regulation 44 of Listing Regulations and Para 3 Clause A (III) of General Circular No. 14/ 2020 dated April 8, 2020 issued by MCA, Government of India, read with General Circular No. 09/ 2024 dated September 19, 2024, General Circular No. 03/ 2025 dated September 22, 2025 and any subsequent General Circular(s) issued by MCA in this regard, the Company has made arrangements for two-way live webcast of the proceedings of AGM.

Details of webcast link shall be made available on the website of the Company at www.strides.com.

Facility for joining the AGM through VC/ OAVM shall be open 30 minutes before the scheduled time for commencement of AGM and shall be closed 30 minutes after such scheduled time.

5) **In view of AGM being held by VC/ OAVM**

i) Physical attendance of Shareholders has been dispensed with;

ii) The facility for appointment of proxies by the Shareholders shall not be available for the AGM and hence Proxy Form and Attendance Slip are not annexed to this Notice;

iii) Shareholders attending the AGM through VC shall be counted for the purpose of reckoning quorum under Section 103 of the Act; and

iv) Route map for the location of the meeting is not provided.

6) **Dividend for FY26**

Board of Directors of the Company in their meeting held on May 18, 2026 have recommended a Final Dividend of Rs. 5/- per equity share of face value of Rs.10/- each for the Financial Year ended March 31, 2026, subject to approval of Shareholders of the Company at the ensuing AGM.

Record Date for entitlement of dividend is Friday, July 31, 2026. The said dividend, if approved by Shareholders, will be paid within 30 days from the date of declaration, subject to deduction of tax at source.

7) **Shareholders who have multiple folios in identical names or joint names** in the same order are requested to intimate the RTA about these folios to enable consolidation of all such shareholdings into one folio.

Strides

GENERAL INFORMATION TO SHAREHOLDERS

1) KYC updation

To prevent fraudulent transactions, Shareholders are advised to exercise due diligence and notify the Company of any change in address, as soon as possible. Further, in case of demise of a Shareholder, their legal heirs are requested to notify the Company, at their earliest convenience.

Shareholders are also advised to not leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned Depository Participant(s) and holdings should be verified from time to time.

Non-Resident Indian Shareholders are requested to inform RTA/ respective Depository participants, immediately of any:

a) Change in their residential status on return to India for permanent settlement; and

b) Particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with pin code, if not furnished earlier.

Procedure for KYC Updation

Shareholders holding shares in electronic form and who have not updated their PAN and KYC are requested to submit the details to their Depository Participant(s).

Shareholders holding shares in physical mode and who have not updated their details are requested to furnish the documents/ details, as per the table below, to Kfintech at their earliest convenience:

Type of Holder	Particulars	Form
Physical	Form for availing investor services to register PAN, email address, bank details and other KYC details or changes/ update thereof for securities held in physical mode.	Form ISR – 1
	Update of signature of securities holder	Form ISR – 2
	Declaration to opt out Nomination	Form ISR-3
	Form for requesting issue of Duplicate Certificate for shares held in physical form.	Form ISR-4
	Request for transmission of Securities by Nominee or Legal Heir.	Form ISR-5
	Nomination form	Form: SH-13
	Cancellation of nomination by the holder(s) (along with ISR-3)/ Change of Nominee	Form: SH-14
Demat	Shareholders to contact their Depository Participants and register their email address and bank account details in their demat account, as per the process advised by the Depository Participants.	

The aforesaid forms can be downloaded from the website of the Company and RTA at:
https://www.strides.com/Shareholders_service_request.html; &
https://ris.kfintech.com/clientservices/isc/isrforms.aspx

Shareholders are requested to forward the duly filled in and executed documents along with the related proofs as mentioned in the respective forms to the following address:

Kfin Technologies Limited
(Formerly known as Kfin Technologies Private Limited),
Unit: Strides Pharma Science Limited
Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda,
Hyderabad – 500 032
Toll Free No.: 1800 309 4001
E-mail: einward.ris@kfintech.com

The above-mentioned ISR Form(s) and the supporting documents can be provided by any one of the following modes:

c) Through 'In Person Verification' (IPV): the authorized person of the RTA shall verify the original documents furnished by the investor and retain copy(ies) with IPV stamping with date and initials;

d) Through hard copies which are self-attested, which can be shared on the address below;

Name	KFIN Technologies Limited Unit: Strides Pharma Science Limited
Address	Selenium Building, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana India – 500 032.

e) Through electronic mode with e-sign by following the link:
https://ris.kfintech.com/clientservices/isc/isrforms.aspx

Detailed FAQ can be found on the link: https://ris.kfintech.com/faq.html

For more information on updating the email and Mobile details **for securities held in electronic mode**, please reach out to the respective DP(s), where the DEMAT A/c is being held.

2) Withdrawal of the requirement of Freezing of Folios

SEBI, vide its Circular No. SEBI/ HO/ MIRSD/ POD-1/ P/ CIR/ 2023/181 dated November 17, 2023, has done away with the requirement of freezing of folios and referring frozen folios to the administering authority under the Benami Transactions (Prohibitions) Act, 1988 and/ or Prevention of Money Laundering Act, 2002.

The aforesaid circular has been incorporated/ updated in the applicable SEBI Master Circular for Registrars to an Issue and Share Transfer Agents issued from time to time, including the Master Circular No. SEBI/ HO/ MIRSD/ MIRSD-PoD/ P/ CIR/ 2025/91 dated June 23, 2025.

3) Dividend Payout to Physical Folios only through Electronic Mode

SEBI vide its Master Circular No. SEBI/HO/MIRSD/ POD-1/P/CIR/2024/37 dated May 7, 2024, has mandated that, with effect from April 1, 2024, dividend to security holders who are holding securities in physical form shall be paid only through electronic mode. Such payment shall be made only after the shareholders furnish their PAN, contact details (postal address with. PIN and mobile number), bank account details and specimen signature (" KYC") and choice of Nomination. As per the aforesaid SEBI Circular, members holding securities in physical form may note that Dividend payable against their shareholdings would be withheld if their KYC details are not updated with the RTA.

Accordingly, Shareholders holding shares in physical form are requested to update their folios with all requisite KYC details, namely PAN, Choice of Nomination, Contact Details including Mobile Number, Bank Account details and Specimen Signature, by submitting the prescribed ISR forms and supporting documents to the RTA.

Upon updation of the aforesaid details in entirety, such Shareholders shall be eligible to receive all unpaid/ unclaimed dividend declared during the period from April 1, 2024, till the date of updation, pertaining to the securities held in such physical folios, automatically through electronic mode.

4) Issue/ Transfer of Shares in dematerialized mode only

Pursuant to Regulation 40 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**Listing Regulations**), as amended from time to time, requests for transfer of securities of listed companies shall be processed only if the securities are held in dematerialized form, except in cases permitted under the applicable SEBI Regulations, circulars or directions issued from time to time.

Further, as an ongoing measure to enhance ease of dealing in securities by investors, SEBI, vide Circular No. SEBI/ HO/ MIRSD/ MIRSD_RTAMB/ P/ CIR/ 2022/ 8 dated January 25, 2022, read with applicable provisions of the SEBI Master Circular for Registrars to an Issue and Share Transfer Agents issued from time to time, including Master Circular No. SEBI/ HO/ MIRSD/ MIRSD-PoD/ P/ CIR/ 2025/ 91 dated June 23, 2025, has mandated that listed companies shall issue securities only in dematerialized form while processing investor service requests such as issue of duplicate securities certificate, claim from unclaimed suspense account, renewal/ exchange of securities certificate, endorsement, sub-division/ splitting of securities certificate, consolidation of securities certificates/ folios, transmission and transposition.

Accordingly, in terms of the applicable SEBI framework:

1. Claimant/ Securities Holder shall submit the relevant service request in Form ISR-4, as hosted on the websites of the Company and RTA, together with requisite documents and details, including demat account particulars, as may be prescribed;

2. The RTA shall verify the request and documents submitted and process the request in accordance with the applicable SEBI Regulations/ circulars, including issuance of Letter of Confirmation, wherever applicable, or such other process as may be prescribed by SEBI from time to time;

3. Where a Letter of Confirmation is issued, the same shall be valid for such period as may be prescribed under the applicable SEBI framework, presently 120 days from the date of its issuance;

4. Claimant/ Securities Holder shall make a request to the Depository Participant for dematerializing the securities within the prescribed period, wherever such step is required under the applicable process;

5. **In case the Claimant/ Securities Holder fails to complete the dematerialization process within the prescribed period, the securities shall be dealt with in the manner prescribed under the applicable SEBI Regulations/ circulars, including credit to the Suspense Escrow Demat Account of the Company, wherever applicable.**

Claimant/ Securities Holder shall thereafter follow the process prescribed by SEBI/ Depositories/ RTA for claiming such securities from the Suspense Escrow Demat Account of the Company or for completion of dematerialization, as applicable.

5) KPRISM – Unified platform for investment monitoring

KPRISM is a unified platform launched by Kfintech for your Equity Investment Monitoring with multiple Self-Help Features.

You may access KPRISM on their website link provided below or through the mobile app named 'KPRISM'.

https://kprism.kfintech.com/

Shareholders can download this android mobile application from play store and view their portfolios serviced by KFintech.

In addition, Shareholders may also visit the Investor Support Center (ISC) webpage at https://ris.kfintech.com/clientservices/isc/default.aspx and access various services such as post or track a query, upload tax exemptions forms, view the demat/ remat request, check the dividend status, download the required ISR forms and check KYC status for physical folios, amongst others.

6) Unclaimed Dividends and Transfer of Dividend and Shares to Investor Education and Protection Fund (IEPF)

In accordance with the provisions of Sections 124 and 125 of the Act and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016 (**IEPF Rules**), Dividends not encashed/ claimed within 7 (seven) years from the date of declaration are to be transferred to the Investor Education and Protection Fund (IEPF) Authority.

IEPF Rules mandates companies to transfer shares of Shareholders whose Dividends remain unpaid/ unclaimed for a continuous period of 7 (seven) years to the demat account of IEPF Authority. Shareholders whose Dividend/ shares are transferred to the IEPF Authority can claim their shares/ Dividend from the Authority.

In accordance with the said IEPF Rules and its amendments, Company has sent reminders to respective Shareholders informing them to claim their unclaimed dividends and shares before it is transferred to IEPF. Transfer of Dividend/ Shares of Shareholders who responded to Company's correspondence was facilitated.

Shareholders may note that no claim shall lie with the Company in respect of unpaid/ unclaimed Dividends and related shares that are already transferred to IEPF.

However, they may claim the same by following the procedure prescribed in the IEPF Rules and by applying in the prescribed Form IEPF-5 available at the MCA Portal at weblink https://www.mca.gov.in/content/mca/global/en/foportal/fologin.html and sending a physical copy of the same to the Nodal Officer of the Company

Shareholders may contact the RTA at einward.ris@kfintech.com or the Company at investors@strides.com to understand and initiate the process.

Company has uploaded details of unpaid/ unclaimed amounts lying with the Company and shares that are transferred to IEPF as at March 31, 2026 on the Company's website at https://www.strides.com/investors/shareholder-information/dividend-shares

7) Inspection of Documents

All documents referred in this AGM Notice shall be available for inspection electronically.

In addition, following documents shall also be available for inspection electronically:

- Certificate from the Secretarial Auditor relating to the Company's Stock Options under SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
- Register of Directors and Key Managerial Personnel and their shareholding, and the Register of Contracts or Arrangements in which the Directors are interested, maintained under the Companies Act, 2013.

Shareholders seeking to inspect the above documents can also send an email to investors@strides.com.

8) Scrutinizer for the AGM

Mr. Gigi Joseph K J, Practicing Company Secretary (ICSI Membership No. F6483 and CP:5576) of M/s. Joseph and Chacko LLP, Company Secretaries, Bengaluru, has been appointed as the Scrutinizer to scrutinize the remote e-voting process and e-voting at the AGM in a fair and transparent manner.

Scrutinizer shall submit his Report on the resolutions proposed to be passed at the AGM to the Chairperson or Company Secretary of the Company after completion of the scrutiny.

Results of the meeting along with Scrutinizer Report shall be declared by the Chairperson or the Company Secretary of the Company on or before Tuesday, August 18, 2026, and shall be communicated to BSE Limited and The National Stock Exchange of India Limited ("Stock Exchanges") where the equity shares of the Company are listed.

Results of the meeting shall also be displayed on the notice board at the Registered Office of the Company for a period of 3 (Three) days, on the Company's website at www.strides.com and on the website of Kfintech at https://evoting.kfintech.com/.

ANNEXURE 2

General instructions for accessing and participating in the AGM through Video Conference/ Other Audio-Visual Means (VC/ OAVM) Facility and voting through electronic means including remote e-voting

I PROCEDURE FOR REMOTE E-VOTING

1 In compliance with the provisions of Section 108 of the Act, read with Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India (ICSI), Regulation 44 of the Listing Regulations, SEBI Circular No. SEBI/ HO/ CFD/ CMD/ CIR/ P/ 2020/ 242 dated December 9, 2020 relating to e-voting facility provided by listed entities, as incorporated/ updated in the applicable SEBI Master Circular for compliance with the provisions of the Listing Regulations issued from time to time, Shareholders are provided with the facility to cast their vote electronically through the e-voting services provided by KFin Technologies Limited (Formerly, KFin Technologies Private Limited) (KFintech/ RTA), on the Resolutions set forth in this Notice.

Shareholders are advised to update their mobile number and email Id in their Demat accounts to access e-Voting facility.

2 Shareholders whose names appear in the Register of Members/ list of Beneficial Owners as on **August 7, 2026 (Cut-off Date)**, are entitled to vote on the Resolutions set forth in this Notice.

Voting rights of the Shareholders shall be in proportion to their shares in the paid-up equity share capital of the Company as at the Cut-off date.

A person who is not a Shareholder as at the Cut-off date should treat this Notice for information purposes only.

Once the vote on a Resolution is cast by the Shareholder, the Shareholder shall not be allowed to change it subsequently.

In case of joint holders, the Shareholder whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.

Shareholders are requested to apply for consolidation of folios, in case their holdings are maintained in multiple folios.

The e-voting facility will be available during the following period:

- **Commencement of e-voting:** 09:00 hrs IST on Monday, August 10, 2026; and
- **End of e-voting:** 17:00 hrs IST on Thursday, August 13, 2026

The remote e-voting will not be allowed beyond the aforesaid date and time and the remote-e-voting module shall be forthwith disabled by KFintech upon expiry of the aforesaid period.

The process and manner of e-voting shall be as under:

Step 1: Access to Depositories e-voting system in case of individual Shareholders holding shares in demat mode.

Step 2: Access to KFintech e-voting system in case of Shareholders holding shares in physical form and non-individual Shareholders in demat mode.

2.1 Details on Step 1 are mentioned below:

Login method for remote e-voting for Individual Shareholders holding securities in demat mode.

NSDL Individual Shareholders holding securities in demat mode with National Securities Depository Limited (NSDL)

I Instructions for existing Internet-based Demat Account Statement ("IDeAS") facility Users:

1) For OTP based login you can click on: https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp.

   You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on the company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

2) Alternatively, you can visit the e-services website of NSDL https://eservices.nsdl.com.

3) On the e-services home page, click on the "**Beneficial Owner**" icon under "Login" under 'IDeAS' section.

4) A new page will open. Enter existing user ID and password for accessing IDeAS.

5) After successful authentication, Shareholders will be able to see e-voting services under 'Value Added Services'.

6) Please click on "Access to e-voting" under e-voting services, after which the e-voting page will be displayed.

7) Click on Company name, i.e., 'Strides Pharma Science Limited', or e-voting service provider, i.e., KFintech.

8) Shareholders will be re-directed to KFintech's website for casting their vote during the remote e-voting period.

II Instructions for those Shareholders who are not registered under IDeAS:

1) Visit https://eservices.nsdl.com for registering.

2) Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp

3) Visit the e-voting website of NSDL https://www.evoting.nsdl.com/.

4) Once the home page of e-voting system is launched, click on the icon "Login" which is available under 'Shareholder/ Member' section. A new screen will open.

5) Shareholders will have to enter their User ID (i.e., the sixteen digits demat account number held with NSDL), password/ OTP and a Verification Code as shown on the screen.

6) After successful authentication, Shareholders will be redirected to NSDL Depository site wherein they can see e-voting page.

7) Click on company name, i.e., 'Strides Pharma Science Limited' or e-voting service provider name, i.e., KFintech, after which the Shareholder will be redirected to e-voting service provider website for casting their vote during the remote e-voting period.

III Users may alternatively vote by directly accessing the e-Voting website of NSDL

1) Open https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.

2) Click on the icon "Login" which is available under 'Shareholder/ Member' section.

3) A new screen will open. You will have to enter your User ID (i.e., your sixteen digit Demat account number held with NSDL), Password/ OTP and a Verification Code as shown on the screen.

4) Post successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page.

5) Click on company name, i.e., 'Strides Pharma Science Limited' or e-voting service provider name, i.e., KFintech, after which the Shareholder will be redirected to e-voting service provider website for casting their vote during the remote e-voting period.

IV NSDL Mobile App

Shareholders can also download the NSDL Mobile App "NSDL Speede" facility by scanning the QR code for seamless voting experience.

CDSL Individual Shareholders holding securities in demat mode with Central Depository Services (India) Limited (CDSL)

1) Users who have opted for CDSL Easi/ Easiest facility, can login through their existing user ID and password. Option will be made available to reach e-voting page without any further authentication.

2) The users to login to Easi/ Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon and New System Myeasi Tab.

Strides

3) After successful login, Easi/ Easiest user will be able to see the e-voting option for eligible companies where the e-voting is in progress as per the information provided by company.

4) On clicking the evoting option, the user will be able to see e-voting page of the e-voting service provider for casting your vote during the remote e-voting period or joining virtual meeting and voting during the meeting, as applicable.

5) Additionally, there is also links provided to access the system of all e-voting Service Providers, so that the user can visit the e-voting service providers' website directly.

6) **If the user is not registered for Easi/ Easiest**, option to register is available at CDSL website www.cdslindia.com and click on login and New System Myeasi Tab and then click on registration option.

7) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from an e-Voting link available on www.cdslindia.com home page.

8) The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account.

9) After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.

I Individual Shareholders login through their demat accounts/ Website of Depository Participant (DP)

1) Shareholders can login using the login credentials of their demat account through their DP registered with the Depositories for e-voting facility.

2) Once logged-in, Shareholders will be able to view e-voting option.

3) Upon clicking on e-voting option, Shareholders will be redirected to the NSDL/ CDSL website after successful authentication, wherein they will be able to view the e-voting feature.

4) Click on options available against 'Strides Pharma Science Limited' or KFintech.

5) Shareholders will be redirected to e-voting website of KFintech for casting their vote during the remote e-voting period without any further authentication.

Important note:

Shareholders who are unable to retrieve User ID/ Password are advised to use 'Forgot user ID' and 'Forgot Password' option available at respective websites.

Helpdesk for individual Shareholders holding securities in demat mode for any technical issues related to login through NSDL/ CDSL

Login type	Helpdesk details
Securities held with NSDL	Please contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or Contact at 022-48867000
Securities held with CDSL	Please contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or Contact at Toll free no.: 1800 22 55 33

2.2 Details on Step 2 are mentioned below:

Login method for Shareholders holding shares in physical form and non-individual Shareholders in demat mode

(A) Instructions for Shareholders whose email IDs are registered with the Company/ Depository Participant(s)

Shareholders whose email IDs are registered with the Company/ Depository Participants will receive an email from KFintech which will include details of E-voting Event Number (EVEN), USER ID and password.

They will have to follow the following process:

a) Launch internet browser by typing the URL: https://evoting.kfintech.com/

b) Enter the login credentials (i.e., User ID and password). In case of physical folio, User ID will be EVEN followed by folio number.

c) In case of Demat account, User ID will be your DPID and Client ID.

d) However, if a Shareholder is registered with K-Fintech for e-voting, they can use their existing User ID and password for casting the vote.

e) After entering these details appropriately, click on "LOGIN".

f) Shareholders will now reach password change Menu wherein they are required to mandatorily change the password.

g) New password shall comprise of minimum 8 characters with at least one upper case (A-Z), one lower case (a-z), one numeric value (0-9) and a special character (@,#,$, etc.,).

h) System will prompt the Shareholder to change their password and update their contact details viz., mobile number, email ID etc.

i) On first login, Shareholders may also enter a secret question and answer of their choice to retrieve their password in case they forget it. It is strongly recommended that Shareholders do not share their password with any other person and that they take utmost care to keep their password confidential.

j) Shareholders would need to login again with the new credentials.

k) On successful login, the system will prompt the Shareholder to select the "EVEN", viz., '**Strides Pharma Science Limited'**, and click on "Submit".

l) On the voting page, the number of shares (which represents the number of votes) held by you as on the cut-off date will appear. If you desire to cast all the votes assenting/ dissenting to the resolution, enter all shares and click 'FOR'/'AGAINST' as the case may be or partially in 'FOR' and partially in 'AGAINST', but the total number in 'FOR' and/or 'AGAINST' taken together should not exceed the total shareholding as mentioned herein above.

m) A Shareholder may also choose the option ABSTAIN.

n) If a Shareholder does not indicate either "FOR" or "AGAINST" it will be treated as "ABSTAIN" and the shares held will not be counted under either head.

o) Shareholders holding multiple folios/ demat accounts shall choose the voting process separately for each folio/ demat account.

p) Shareholders may then cast their vote by selecting an appropriate option and click on "Submit".

q) A confirmation box will be displayed. Click "OK" to confirm else "CANCEL" to modify.

r) Once Shareholder have voted on the resolution(s), they will not be allowed to modify their vote. During the voting period, Shareholder can login any number of times till they have voted on the Resolution.

s) Corporate/ Institutional members (corporate / FIs / FIIs / trust / mutual funds / banks, etc.,) are required to send scanned copy (pdf format) of the relevant board resolution to the Scrutinizer through e-mail to gigi@jandc.in with a copy to evoting@kfintech.com.

t) The file scanned image/ pdf file of the board resolution should be in the naming format "Corporate Name".

(B) Instructions for Shareholders whose email IDs are not registered with the Company / Depository Participant(s), and consequently the AGM Notice and e-voting instructions cannot be serviced:

Shareholders are requested to follow the process as guided to capture the email address and mobile number for receiving the soft copy of the AGM Notice and e-voting instructions along with the User ID and Password. In case of any queries, Shareholders may write to einward.ris@kfintech.com.

(C) Method for obtaining used id and password for Shareholders who have forgotten the User ID and password

Shareholders who have forgotten the user id and password, may obtain/ retrieve the same in the manner mentioned below:

If the mobile number of the Shareholder is registered against Folio No. / DP ID Client ID, the Shareholder may send SMS: MYEPWD<space>E-voting Event Number (EVEN) +

Strides

Folio No. or DP ID Client ID to +91 9212993399

Example for NSDL: MYEPWD<SPACE>IN12345612345678
Example for CDSL: MYEPWD<SPACE>1402345612345678
Example for Physical: MYEPWD<SPACE> XXXX1234567890

If email ID of the Shareholder is registered against Folio No. / DP ID Client ID, then on the home page of https://evoting.kfintech.com, the Shareholder may click 'Forgot password' and enter Folio No. or DP ID Client ID and PAN to generate a password.

Shareholders may send an email request to einward.ris@kfintech.com.

If the Shareholder is already registered with the KFintech e-voting platform then such Shareholder can use his/ her existing User ID and password for casting the vote through remote e-voting.

Shareholders may call KFintech toll free number 1-800-309-4001 for any clarifications / assistance that may be required.

(D) In case of any queries, you may refer the Frequently Asked Questions (FAQs) for shareholders and e-voting User Manual for shareholders available at the download section of https://evoting.kfintech.com/public/Faq.aspx.

II INSTRUCTIONS FOR ATTENDING THE AGM OF THE COMPANY THROUGH VC/ OAVM AND E-VOTING DURING THE MEETING

(i) Shareholders shall be provided with a facility to attend the AGM through VC/ OAVM platform provided by KFintech.

Shareholders may access the same at https://emeetings.kfintech.com/ by using the e-voting login credentials provided in the email received from the Company/ KFintech.

The link for attending the meeting will be available in Shareholders login, where the EVENT and the name of the Company can be selected.

Click on the video symbol and accept the meeting etiquettes to join the meeting. Please note that the Shareholders who do not have the User ID and Password for e-voting or have forgotten the User ID and Password may retrieve the same by following the remote e-voting instructions mentioned above.

Shareholders are encouraged to join the meeting through devices (Laptops, Desktops, Mobile devices) with Google Chrome for seamless experience.

Further, Shareholders registered as speakers will be required to allow camera during e-AGM and hence are requested to use internet with a good speed to avoid any disturbance during the meeting.

Shareholders may join the meeting using headphones for better sound clarity.

(ii) While all efforts would be made to make the meeting smooth, participants connecting through mobile devices, tablets, laptops, etc., may at times experience audio/ video loss due to fluctuation in their respective networks. Use of a stable Wi-Fi or LAN connection can mitigate some of the technical glitches.

(iii) Facility of joining the AGM through VC/ OAVM shall be available for at-least 1,000 Shareholders on first come first served basis.

However, the above restriction shall not be applicable to Shareholders holding 2% or more shareholding, Promoters, Institutional Investors, Directors, Key Managerial Personnel(s), the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors, Scrutinizers etc.

Institutional Shareholders are encouraged to attend and vote at the AGM through VC/ OAVM.

(iv) Facility for joining the AGM through VC/ OAVM will be open 30 minutes before the scheduled time for commencement of AGM and shall be closed 30 minutes after such scheduled time.

Only bona fide Shareholders of the Company whose names appear on the Register of Members, will be permitted to attend the meeting through VC/ OAVM.

The Company reserves its right to take all necessary steps as may be deemed necessary to restrict non-Shareholders from attending the meeting.

(v) A Shareholder can opt for only single mode of voting i.e., through remote e-voting or e-voting at the AGM.

If a Shareholder cast votes by both modes, then voting done through remote e-voting shall prevail and voting at the AGM shall be treated as invalid.

Shareholders who have not cast their vote through remote e-voting shall be eligible to cast their vote through e-voting system available during the AGM.

E-voting during the AGM is integrated with the VC/ OAVM platform. Shareholders may click on the voting icon displayed on the screen to cast their votes.

(vi) Speaker Registration and Post your Questions facility

Shareholders, who would like to express their views or ask questions during the AGM will have to register themselves as a speaker by visiting the URL https://emeetings.kfintech.com/ and clicking on the tab 'Speaker Registration' during the period starting from Monday, August 10 , 2026 (09:00 hrs IST) up to Wednesday, August 12, 2026 (17:00 hrs IST).

Only those Shareholders who have registered themselves as a speaker will be allowed to express their views/ ask questions during the AGM.

When a pre-registered speaker is invited to speak at the meeting but he/ she does not respond, the next speaker will be invited to speak.

Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM. Only questions of the Shareholders holding shares as on the **cut-off** date will be considered.

A video guide assisting the Shareholders attending AGM either as a speaker or participant is available for quick reference at URL https://emeetings.kfintech.com/, under the "How It Works" tab placed on top of the page.

Strides

Shareholders who need technical assistance before or during the AGM can contact RTA at Helpline: 1800 309 4001.

(vii) In case a person has become a Shareholder of the Company after dispatch of AGM Notice but on or before the **cut-off** date for e-voting, he/ she may obtain the User ID and Password in the manner as mentioned below:

If the mobile number of the Shareholder is registered against Folio No. / DP ID Client ID, the Shareholder may send SMS: MYEPWD <space> E-voting Event Number (EVEN) + Folio No. or DP ID Client ID to +91 9212993399

Example for NSDL: MYEPWD<SPACE>IN12345612345678
Example for CDSL: MYEPWD<SPACE>1402345612345678

Example for Physical: MYEPWD<SPACE> XXXX1234567890

If email ID of the Shareholder is registered against Folio No. / DP ID Client ID, then on the home page of https://evoting.kfintech.com, the Shareholder may click 'Forgot password' and enter Folio No. or DP ID Client ID and PAN to generate a password.

Shareholders may send an email request to einward.ris@kfintech.com.

If the Shareholder is already registered with the KFintech e-voting platform then such Shareholder can use his/ her existing User ID and password for casting the vote through remote e-voting.

Shareholders who may require any technical assistance or support before or during the AGM are requested to contact KFintech at toll free number 1-800-309-4001 or write to them at evoting@kfintech.com.

(viii) In case of any query and/ or grievance, in respect of voting by electronic means through KFintech, Shareholders may:

- Refer to the Help and Frequently Asked Questions (FAQs) and e-voting user manual available at the download section of https://evoting.kfintech.com ;or

- Contact Mr. Sashidhar Mannava, Vice President-Corporate Registry or Mr. Mohan Kumar A, Senior Manager of M/s. KFin Technologies Limited, Selenium, Tower B, Plot 31 and 32, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad – 500 032, India; or

- Reach out to the Toll Free No.: 1800 309 4001; or E-mail: einward.ris@kfintech.com; evoting@kfintech.com.

*****